The emergence of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable excitement within the healthcare community. This innovative dual GIP and GLP-1 agonist medication appears to offer notable improvements in fat shedding compared to current therapies. Initial patient data have indi